[go: up one dir, main page]

TN2014000147A1 - Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique - Google Patents

Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique

Info

Publication number
TN2014000147A1
TN2014000147A1 TNP2014000147A TN2014000147A TN2014000147A1 TN 2014000147 A1 TN2014000147 A1 TN 2014000147A1 TN P2014000147 A TNP2014000147 A TN P2014000147A TN 2014000147 A TN2014000147 A TN 2014000147A TN 2014000147 A1 TN2014000147 A1 TN 2014000147A1
Authority
TN
Tunisia
Prior art keywords
phenylimidazol
sodium channel
derivatives useful
channel modulators
ethylamine derivatives
Prior art date
Application number
TNP2014000147A
Other languages
English (en)
Inventor
Sharanjeet Kaur Bagal
Mark Ian Kemp
Duncan Charles Miller
Yoshihisa Murata
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000147(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of TN2014000147A1 publication Critical patent/TN2014000147A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des dérivés d'imidazole, leur utilisation en médecine, des compositions les contenant, des procédés pour leur préparation et des intermédiaires utilisés dans de tels procédés. L'invention concerne plus particulièrement de nouveaux modulateurs imidazole du Nav1.8 de formule (I) ou un sel pharmaceutiquement acceptable de ceux-ci, les R1, R2, R3, R4 et R5 étant tels que définis dans la description. Les modulateurs du Nav1.8 sont potentiellement utiles dans le traitement d'une large gamme de troubles, en particulier de la douleur.
TNP2014000147A 2011-10-26 2014-04-08 Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique TN2014000147A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26
PCT/IB2012/055610 WO2013061205A2 (fr) 2011-10-26 2012-10-15 Composés chimiques

Publications (1)

Publication Number Publication Date
TN2014000147A1 true TN2014000147A1 (fr) 2015-09-30

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2014000147A TN2014000147A1 (fr) 2011-10-26 2014-04-08 Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique

Country Status (28)

Country Link
US (1) US9079878B2 (fr)
EP (1) EP2771335A2 (fr)
JP (1) JP5946538B2 (fr)
KR (1) KR101586966B1 (fr)
CN (1) CN103906746B (fr)
AP (1) AP2014007579A0 (fr)
AU (1) AU2012328034B2 (fr)
BR (1) BR112014009102A2 (fr)
CA (1) CA2850925C (fr)
CL (1) CL2014000956A1 (fr)
CO (1) CO6940427A2 (fr)
CR (1) CR20140185A (fr)
CU (1) CU20140046A7 (fr)
DO (1) DOP2014000085A (fr)
EA (1) EA023375B1 (fr)
EC (1) ECSP14013324A (fr)
GT (1) GT201400079A (fr)
IL (1) IL232267A (fr)
MD (1) MD20140037A2 (fr)
MX (1) MX337469B (fr)
NI (1) NI201400031A (fr)
PE (1) PE20141682A1 (fr)
PH (1) PH12014500919A1 (fr)
SG (1) SG11201401032YA (fr)
TN (1) TN2014000147A1 (fr)
UA (1) UA109220C2 (fr)
WO (1) WO2013061205A2 (fr)
ZA (1) ZA201402281B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1199262A1 (en) * 2011-09-14 2015-06-26 Dow Agrosciences Llc Methods and systems for forming boronic acids and intermediates thereof
AP2016009287A0 (en) 2013-12-13 2016-06-30 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
CA2965509C (fr) 2014-10-24 2023-03-14 Avectas Limited Administration a travers des membranes plasmiques de cellules
JP6762308B2 (ja) 2015-02-19 2020-09-30 パーデュー、ファーマ、リミテッド、パートナーシップ 胃排出の減少方法及び組成物
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
WO2017115128A2 (fr) 2015-12-30 2017-07-06 Avectas Limited Administration sans vecteur de protéines et de compositions d'édition de gènes dans des cellules et des tissus
US11459587B2 (en) 2016-07-06 2022-10-04 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
DK3481856T3 (da) * 2016-07-06 2025-11-10 Vertex Pharma Materialer og metoder til behandling af smerterelaterede lidelser
CA3063901A1 (fr) 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Amides de pyridone deuteres et leurs promedicaments utilises en tant que modulateurs de canaux sodiques
CR20200064A (es) 2017-07-11 2020-08-03 Vertex Pharma Carboxamidas como moduladores de los canales de sodio
CA3091012A1 (fr) 2018-02-12 2019-08-15 Vertex Pharmaceuticals Incorporated Methode de traitement de la douleur
GEP20237568B (en) 2018-11-02 2023-11-27 Merck Sharp & Dohme Llc 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
WO2020146612A1 (fr) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters et carbamates utilisés en tant que modulateurs de canaux sodiques
WO2020146682A1 (fr) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides utilisés en tant que modulateurs de canaux sodiques
WO2020176763A1 (fr) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Forme posologique comprenant un promédicament inhibiteur de canal sodique na 1,8
WO2020219867A1 (fr) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Compositions de co-cristaux d'amide de pyridone pour le traitement de la douleur
JOP20220130A1 (ar) 2019-12-06 2023-01-30 Vertex Pharma مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
WO2022256622A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques
EP4347584A1 (fr) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Analogues de n-(hydroxyalkyl(hétéro)aryl)tétrahydrofurane carboxamide en tant que modulateurs de canaux sodiques
JP2024520648A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド
CA3222197A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Formes galeniques solides et schemas posologiques comprenant du (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
CN117858875A (zh) 2021-06-04 2024-04-09 沃泰克斯药物股份有限公司 羟基和(卤代)烷氧基取代的四氢呋喃作为钠通道调节剂
WO2022256676A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Analogues de tétrahydrofurane substitués utiles en tant que modulateurs de canaux sodiques
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
JP2025513454A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CN119522214A (zh) 2022-04-22 2025-02-25 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
KR20250006217A (ko) 2022-04-25 2025-01-10 사이트원 테라퓨틱스, 인코포레이티드 통증 치료를 위한 Naν1.8의 바이사이클릭 헤테로사이클릭 아미드 억제제
CN115656380B (zh) * 2022-11-09 2025-04-01 武汉海特生物创新医药研究有限公司 一种mtv对映异构体的hplc-uv检测方法
CN120603815A (zh) 2022-12-06 2025-09-05 沃泰克斯药物股份有限公司 钠通道的取代四氢呋喃调节剂的合成方法
WO2025090511A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Procédés de préparation de modulateurs de canaux sodiques et formes solides de ceux-ci pour le traitement de la douleur
WO2025090465A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Composés hétéroaryle pour le traitement de la douleur
WO2025090480A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Composés hétéroaryles pour le traitement de la douleur
WO2025090516A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Procédés de préparation de composés pour le traitement de la douleur et de formes solides de ceux-ci
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (fr) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyle et inhibiteurs d'hétérocycloalkyle de nav1.8 pour le traitement de la douleur

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI292316B (en) * 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
BRPI0510664B8 (pt) * 2004-05-07 2021-05-25 Warner Lambert Co derivados de fenol e tiofenol 3 ou 4-monosubstituído, composição farmacêutica, combinação e uso dos compostos para tratamento de doenças relacionadas ao h3, incluindo transtornos do sistema nervoso central e transtornos inflamatórios
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP2371954A1 (fr) * 2004-10-27 2011-10-05 Schering Corporation Compositions et procédés d'inhibition par des petits acides nucléiques interférents dirigés contre NAv1.8
CA2629065C (fr) * 2005-12-22 2013-08-06 Newron Pharmaceuticals S.P.A. Derives 2-phenylethylamino en tant que modulateurs du canal calcium et/ou sodium
MX2009004233A (es) 2006-10-18 2009-08-12 Pfizer Prod Inc Compuestos de biaril eter urea.
DE602008000809D1 (de) 2007-03-23 2010-04-29 Icagen Inc Ionenkanal-Hemmer
EP2183241B1 (fr) 2007-05-03 2012-12-19 Pfizer Limited Derives de 2-pyridine carboxamide comme modulateurs des canaux de sodium
EP2155727A1 (fr) * 2007-05-03 2010-02-24 Pfizer Limited Dérivés n-[6-amino-5-(phényl)pyrazin-2-yl]-isoxazole-4-carboxamide et composés similaires en tant que modulateurs du canal nav1.8 pour le traitement de la douleur
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors

Also Published As

Publication number Publication date
CU20140046A7 (es) 2014-10-02
DOP2014000085A (es) 2014-08-31
US9079878B2 (en) 2015-07-14
IL232267A (en) 2016-10-31
GT201400079A (es) 2015-06-02
NI201400031A (es) 2014-10-01
BR112014009102A2 (pt) 2017-04-18
PE20141682A1 (es) 2014-11-14
MX2014004738A (es) 2014-08-01
IL232267A0 (en) 2014-06-30
EA023375B1 (ru) 2016-05-31
CN103906746B (zh) 2015-12-09
WO2013061205A2 (fr) 2013-05-02
AP2014007579A0 (en) 2014-04-30
CA2850925A1 (fr) 2013-05-02
JP2014530900A (ja) 2014-11-20
ZA201402281B (en) 2015-11-25
CO6940427A2 (es) 2014-05-09
PH12014500919A1 (en) 2014-06-09
AU2012328034A1 (en) 2014-05-15
SG11201401032YA (en) 2014-07-30
WO2013061205A8 (fr) 2014-03-27
CL2014000956A1 (es) 2014-07-18
ECSP14013324A (es) 2014-05-31
HK1198650A1 (en) 2015-05-22
JP5946538B2 (ja) 2016-07-06
US20140296313A1 (en) 2014-10-02
KR20140069234A (ko) 2014-06-09
AU2012328034B2 (en) 2015-04-23
WO2013061205A3 (fr) 2013-06-27
EP2771335A2 (fr) 2014-09-03
CN103906746A (zh) 2014-07-02
CR20140185A (es) 2014-06-03
MD20140037A2 (ro) 2014-08-31
KR101586966B1 (ko) 2016-01-19
NZ623090A (en) 2015-10-30
MX337469B (es) 2016-03-02
EA201490864A1 (ru) 2014-08-29
UA109220C2 (uk) 2015-07-27
CA2850925C (fr) 2017-01-10

Similar Documents

Publication Publication Date Title
TN2014000147A1 (fr) Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA35128B1 (fr) Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA32965B1 (fr) Derives de sulfonamides
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA50240B1 (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA45223A (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA43756B1 (fr) Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
MA31419B1 (fr) Derives de pyridine
MA42232B1 (fr) Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant
MA30932B1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa -carboxylase
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA29926B1 (fr) Derives de pyrazine
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA34308B1 (fr) Triazolopyridines substituées
MA38999A1 (fr) Nouveaux composés hétérocycliques
MA29839B1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c